definiens: and means all anti - CD19 Antibodies that do not contain any of the Fc variants in Exhibit D ( as is defined in Exhibit D ) and that both ( 1 ) ( meaning either of ( a ) or ( b ) ), and ( 2 ): ( 1 ) either of : ( a ) the Fc of such Antibody contains solely a variant l isted in Exhibit C ( as is defined in Exhibit C ) ; provided, however, that such Antibody is [ … * * * … ] ; or ( b ) [ … * * * … ] than [ … * * * … ] and [ … * * * … ] ( i ) such Antibody [ … * * * … ] by [ … * * * … ] compared to [ … * * * … ] compared to [ … * * * … ] ( [ … * * * … ] ) of [ … * * * … ], and [ … * * * … ] that is [ … * * * … ] than [ … * * * … ], and ( ii ) such Antibody does not have [ … * * * … ] that is [ … * * * … ] of [ … * * * … ], and does not have [ … * * * … ] that is [ … * * * … ] AND ( 2 ) [ … * * * … ] ARTICLE 2 COLLABORATION MANAGEMENT AND DEVELOPMENT REPORTING 2.1 Overview . Initially, [COMPANY] shall initiate and shall, subje ct to Sec . 2.2, 2.4, 2.5 and 3.11 hereof, continue to sponsor the Ongoing Phase 1 Tri al, to the extent provided for in more detail below in Sections 3.1 through 3.3 . Other than the Ongoing Ph ase 1 Trial, [COMPANY] shall have sole responsibili ty for development and commercialization of the Licensed A ntibody(ies ) and/or Licensed Products for the Field during the Term . Information sharing, plan sharing, collab oration, coordination and development reporting bet ween the Parties shall be as described in this Article 2 . Te chnology transfer, regulatory transfer, and further development and commercialization obligations are as described in Article 3